Equities research analysts expect that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report $40.30 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Sangamo Therapeutics’ earnings. The lowest sales estimate is $33.49 million and the highest is $47.10 million. Sangamo Therapeutics posted sales of $11.81 million during the same quarter last year, which suggests a positive year over year growth rate of 241.2%. The company is expected to announce its next earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Sangamo Therapeutics will report full year sales of $91.13 million for the current fiscal year, with estimates ranging from $59.00 million to $112.30 million. For the next year, analysts forecast that the company will post sales of $99.90 million, with estimates ranging from $50.00 million to $132.10 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The company had revenue of $21.42 million for the quarter, compared to analysts’ expectations of $21.43 million. During the same period in the prior year, the firm earned ($0.17) earnings per share. The firm’s quarterly revenue was up 159.6% on a year-over-year basis.

A number of brokerages recently weighed in on SGMO. BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. Guggenheim began coverage on shares of Sangamo Therapeutics in a research report on Tuesday, October 9th. They set a “buy” rating and a $18.00 price target for the company. Zacks Investment Research raised shares of Sangamo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Wedbush reaffirmed a “hold” rating and set a $9.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, July 24th. Finally, ValuEngine cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Sangamo Therapeutics presently has an average rating of “Buy” and an average target price of $21.00.

In other news, Director H Stewart Parker acquired 2,000 shares of the business’s stock in a transaction on Friday, September 7th. The shares were purchased at an average price of $13.52 per share, for a total transaction of $27,040.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $13.45, for a total transaction of $67,250.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,000 shares of company stock valued at $430,950. 1.20% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in Sangamo Therapeutics by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after buying an additional 234,346 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Sangamo Therapeutics by 14.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock worth $8,032,000 after buying an additional 71,134 shares in the last quarter. Platinum Investment Management Ltd. acquired a new position in Sangamo Therapeutics in the 2nd quarter worth $751,000. Bain Capital Public Equity Management LLC acquired a new position in Sangamo Therapeutics in the 2nd quarter worth $2,002,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in Sangamo Therapeutics by 193.6% in the 1st quarter. Cubist Systematic Strategies LLC now owns 65,087 shares of the biopharmaceutical company’s stock worth $1,237,000 after buying an additional 42,917 shares in the last quarter. Hedge funds and other institutional investors own 63.75% of the company’s stock.

Sangamo Therapeutics stock traded down $0.30 during trading on Friday, reaching $13.89. 1,405,700 shares of the company’s stock were exchanged, compared to its average volume of 2,257,301. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07. Sangamo Therapeutics has a 52-week low of $11.30 and a 52-week high of $27.50. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -20.13 and a beta of 2.97.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.